Related Experiment Video
Updated: Jun 5, 2026

A Multicenter MRI Protocol for the Evaluation and Quantification of Deep Vein Thrombosis
Published on: June 2, 2015
Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients
Desiree E Morgan1, J Stephen Spann, Mark E Lockhart
1Department of Radiology, University of Alabama at Birmingham, 619 19th St S, JT N322, Birmingham, AL 35233, USA. dmorgan@uabmc.edu
Purpose:
To determine adverse reaction rates in a tertiary care clinical setting after adoption of gadoteridol as the institutional routine magnetic resonance (MR) imaging contrast agent.
Materials And Methods:
With institutional review board approval, informed consent waiver, and HIPAA compliance, a prospective observational study of 28 078 patients who underwent intravenous gadoteridol-enhanced MR imaging from July 2007 to December 2009 was performed. Reactions were recorded by technologists who noted types of reactions, method of injection, and treatment. Reactions were classified as mild, moderate, or severe per American College of Radiology definitions. Comparisons of reaction rates with dose and method of injection were analyzed with the Fisher exact and χ(2) tests.
Results:
Overall reaction rate was 0.666% (187 patients), including 177 mild, six moderate, and four severe reactions. Treatment was given in 27 patients (14.4%). The most frequent reaction was nausea (and/or vomiting) in 149 patients (79.7% of patients with any adverse reaction, 0.530% of overall population). Method of injection did not affect reaction rate or severity. There was no difference in type or severity of reactions in comparison of patients receiving half the dose versus patients receiving the standard dose (P = .33-.75).
Conclusion:
The observed adverse reaction rate to gadoteridol was lower than previously reported. Specifically, the rate of nausea (0.530%) was less than half the rate (1.4%) in clinical trials of 1251 patients, leading to FDA approval in 1992. Rates of adverse reactions for this macrocyclic contrast agent are comparable to those published for linear gadolinium-based contrast agents.
Insights
Adverse reaction rates for gadoteridol MRI contrast were low, with nausea being the most common issue. This macrocyclic agent
Area of Science:
- Radiology
- Pharmacovigilance
- Medical Imaging
Background:
- Gadolinium-based contrast agents (GBCAs) are essential for magnetic resonance (MR) imaging.
- Gadoteridol is a macrocyclic GBCA used institutionally.
- Monitoring adverse reactions is crucial for patient safety.
Purpose of the Study:
- To determine the adverse reaction rates associated with gadoteridol.
- Evaluate reactions in a large patient cohort undergoing routine MR imaging.
- Compare observed rates with previously reported data.
Main Methods:
- Prospective observational study of 28,078 patients receiving intravenous gadoteridol.
- Adverse reactions were documented by technologists and classified by severity.
- Statistical analysis using Fisher exact and chi-squared tests.
Main Results:
- Overall adverse reaction rate was 0.666% (187 patients).
- Nausea/vomiting was the most frequent reaction (0.530% of all patients).
- Injection method and dose did not significantly impact reaction rates or severity.
Conclusions:
- The observed adverse reaction rate for gadoteridol was lower than previously reported.
- Nausea rates were significantly lower than those in clinical trials leading to FDA approval.
- Gadoteridol exhibits comparable safety to linear gadolinium-based contrast agents.
Related Concept Videos
Imaging Studies I: CT and MRI
Description of the Procedures
Computed Tomography (CT) scan:
Computed Tomography (CT) scans use X-ray technology to generate detailed images of bones, organs, and tissues. During the scan, the patient lies on a moving table...
Imaging Studies III: Computed Tomography
Imaging Studies for Cardiovascular System IV: CMRI
Imaging Studies for Cardiovascular System V: CT
Radiological Investigation I: X-ray and CT
Magnetic Resonance Imaging

